CCR5 and neoplasm: Similar to the MMTV-PyMT transplant study, NSG mice transplanted with MDA-MB-231.CCR5−/− cells exhibited a lower tumor load (Fig. 5a) and on average a 3.96 day delay in tumor onset (Fig. 5b).